Talon Private Wealth LLC Invests $839,000 in Halozyme Therapeutics, Inc. $HALO

Talon Private Wealth LLC purchased a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 10,725 shares of the biopharmaceutical company’s stock, valued at approximately $839,000.

Other hedge funds have also recently bought and sold shares of the company. Horizon Investment Services LLC acquired a new stake in Halozyme Therapeutics in the 2nd quarter valued at about $2,254,000. Chase Investment Counsel Corp purchased a new position in Halozyme Therapeutics during the 2nd quarter valued at about $2,035,000. Mizuho Markets Americas LLC raised its position in Halozyme Therapeutics by 270.8% during the fourth quarter. Mizuho Markets Americas LLC now owns 1,268,673 shares of the biopharmaceutical company’s stock worth $85,382,000 after acquiring an additional 926,526 shares during the last quarter. Great Lakes Advisors LLC acquired a new position in Halozyme Therapeutics during the second quarter worth about $2,821,000. Finally, Aurora Investment Counsel purchased a new stake in shares of Halozyme Therapeutics in the second quarter valued at about $1,427,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Trading Up 0.2%

Shares of Halozyme Therapeutics stock traded up $0.20 during mid-day trading on Friday, hitting $107.20. 861,533 shares of the stock were exchanged, compared to its average volume of 1,843,557. The stock has a market capitalization of $12.17 billion, a price-to-earnings ratio of 32.00, a price-to-earnings-growth ratio of 0.42 and a beta of 0.88. Halozyme Therapeutics, Inc. has a twelve month low of $61.22 and a twelve month high of $111.15. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The company has a 50-day simple moving average of $93.18 and a 200 day simple moving average of $76.75.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. During the same quarter in the previous year, the business posted $1.54 earnings per share. The company’s revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Research analysts forecast that Halozyme Therapeutics, Inc. will post 7.98 EPS for the current year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $104.18, for a total transaction of $2,083,600.00. Following the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at $79,987,320.40. This represents a 2.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the sale, the director owned 40,418 shares in the company, valued at $4,154,970.40. This trade represents a 3.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 32,478 shares of company stock valued at $3,076,604 in the last quarter. 2.50% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Citizens Jmp increased their price target on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a research report on Friday, August 7th. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. UBS Group reaffirmed a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Wall Street Zen upgraded Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Finally, Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $91.20.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company’s primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.